Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 11, 2024

Impact of Biomarker Testing on Treatment Selection and Outcomes

A panel of experts discuss the importance of up-front biomarker testing.

Episodes in this series

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

A panel of 4 experts on lung cancer

EP. 11 Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

A panel of 4 experts on lung cancer

EP. 12 Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

A panel of 4 experts on lung cancer

EP. 13 Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Video content above is prompted by the following:

How could increasing adherence to testing guidelines potentially impact treatment selection and patient outcomes?
- Why is biomarker testing so important up front?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Unmet Needs and Emerging Mechanisms of Action in Extrapulmonary Neuroendocrine Carcinoma: The Path Toward Better Therapies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Risk Stratification and Weight Loss as Therapy: A Hepatologist's Framework for Managing MASH Progression

ByNadege Gunn, MD

July 10th 2026

Screening MASH Upstream: Building a Practical, Scalable Algorithm for the Real World

ByNadege Gunn, MD

July 10th 2026

Experts featured in this series.

Fixing the Mental Health System: Burnout, Advocacy, and the Case for Team-Based Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: July 7th 2026 | Updated: June 16th 2026

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Home-Based Heart Failure Care Shows Comparable Safety to Continued Inpatient Care

Cardiology Prices Vary Widely by Insurer and State

Voice Biomarkers Show Promise for Asthma, COPD Exacerbation Detection

Rethinking Cardiometabolic Risk: Deepak Bhatt, MD, MPH, MBA